Prenetics Global Ltd (PRE)
2.94
-0.25
(-7.84%)
USD |
NASDAQ |
Apr 19, 16:00
2.94
0.00 (0.00%)
After-Hours: 17:03
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 35.88M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -74.63% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.0985 |
| Price to Book Value | 0.1599 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong. |
| URL | https://www.prenetics.com |
| Investor Relations URL | https://ir.prenetics.com/ |
| HQ State/Province | N/A |
| Sector | |
| Industry | |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Jun. 05, 2024 (est.) |
| Last Earnings Release | Apr. 02, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong. |
| URL | https://www.prenetics.com |
| Investor Relations URL | https://ir.prenetics.com/ |
| HQ State/Province | N/A |
| Sector | |
| Industry | |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Jun. 05, 2024 (est.) |
| Last Earnings Release | Apr. 02, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |